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Abstract: Amyloids were first identified in association with amyloidoses, human diseases in which
proteins and peptides misfold into amyloid fibrils. Subsequent studies have identified an array of
functional amyloid fibrils that perform physiological roles in humans. Given the potential for the
production of toxic species in amyloid assembly reactions, it is remarkable that cells can produce
these functional amyloids without suffering any obvious ill effect. Although the precise mechanisms
are unclear, there are a number of ways in which amyloid toxicity may be prevented. These include
regulating the level of the amyloidogenic peptides and proteins, minimising the production of
prefibrillar oligomers in amyloid assembly reactions, sequestrating amyloids within membrane
bound organelles, controlling amyloid assembly by other molecules, and disassembling the fibrils
under physiological conditions. Crucially, a better understanding of how toxicity is avoided in the
production of functional amyloids may provide insights into the prevention of amyloid toxicity
in amyloidoses.
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1. Introduction
Amyloid fibrils are cross-β assemblies and were first identified in amyloidoses, an array
of devastating human diseases [1–3]. To date, over 30 different sequences are now known to
misfold to form amyloids in amyloidoses, including amyloid-β (Aβ) in Alzheimer’s disease,
α-synuclein in Parkinson’s disease, huntingtin in Huntington’s disease, and β2-microglobulin (β2m)
in dialysis-related amyloidosis (DRA) [4–7]. Crucially, amyloid formation can result in degeneration of
the affected tissue [5,8]. This intimate association with human disease led to amyloid fibril assembly
being considered as a pathological process. It was therefore surprising to discover that amyloid fibrils
perform physiological functions in organisms ranging from prokaryotes to humans [9,10]. In humans,
functional amyloids have been proposed to participate in an array of physiological processes including
pigmentation, the storage of peptide hormones, the fertilisation of oocytes by sperm, antimicrobial
responses, regulated necrosis, and cellular responses to stress [11–21]. Nonetheless, the toxicity of
amyloid formation in amyloidoses raises an important question that this review article will address,
namely, how under normal circumstances can human cells produce functional amyloid fibrils without
suffering any obvious deleterious effects?
2. Amyloid Fibril Assembly and Structure
The assembly of amyloid fibrils from their peptide and protein precursors is a nucleation
dependent process [6,7]. There is an initial lag phase, which ends in the formation of a fibril nucleus
(Figure 1) [6,7]. This initiates the exponential phase in which fibrils assemble, before fibril growth then
plateaus in the equilibrium phase [6,7]. The resultant amyloid fibrils are unbranched fibres of 5–15 nm
in width, composed of two or more protofilaments and can be many microns in length [6,7]. Within
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the protofilaments, the individual subunits form a cross-β structure, corresponding to ribbon-like
arrays of β-sheets that are aligned perpendicular to the long axis of the fibril (Figure 1) [6,7,22].
The cross-β structure of amyloid fibrils produces a distinctive X-ray fiber diffraction pattern, with
reflections at 4.7 Å and ~10 Å, corresponding to the hydrogen bonding distances between β-strands
and side chain packing between the sheets, respectively [3]. Amyloid fibrils also have characteristic
tinctorial properties, binding to the dyes thioflavin-S, thioflavin-T, and Congo red, the latter exhibiting
green birefringence in polarised light when bound to amyloids [3]. In addition, antibodies that
recognise conformational epitopes in amyloid fibrils and their assembly intermediates have been
generated [23–25].
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inherent potential to produce toxic species irrespective of the amyloidogenic precursor. Analyses of 
the mechanisms of toxicity have revealed that cellular membranes are a major target for prefibrillar 
Figure 1. A yloid fibril assembly. Amyloid fibril assembly is nucleation dependent. There is an initial
lag phase, populated by prefibrillar oligomers, which ends with the production of the fibril nucleus.
Fibrils then assemble in an exponential manner until the amyloidogenic precursor is exhausted. The
resultant fibrils are composed of two or more protofilaments. Within each protofilament, the subunits
have a cross-β core, corresponding to β-sheets aligned perpendicular to the long-axis of the fibril.
Although the core of all amyloid fibrils is a cross-β structure, and hence the fibrils share some
common properti s, th precise arrangement of the subunits in the protofilaments is dependent on th
precursor [6,7,22]. Moreover, amyloid fibrils exhibit heterogeneity, with the sa e precursor being able
to produce self-propagating fibril polymorphs with distinctiv molecular structures, or hologies,
and biological r perties [26,27].
3. The Amyloidoses and Mechanisms of Amyloid Toxicity
Amyloid fibrils generated in amyloidoses represent abnormal aggregates that result from the
misfolding of the precurso p pt de or pr tein [6,7]. These amyl id fibrils can d posit into extracellular
plaques, as observed in Alzheim r’s isease and dialysis-relat d amyloidosis, where s in Park nson’s
and Huntington’s amyloids are present in intracellular inclusions [5]. Identifying the specie produced
amyloid assembly reactions th t are the cul it of tox city in amyloido es and elucidating their
m hanisms of action is a priority. A plethora of experimental studies have shown that prefibrillar
oligomers produced in the lag phase of amyloid assembly reactions ar toxic both in itro and
in vivo [28,29]. Crucially, toxic prefibrillar oli omers are not unique to the p ptides and proteins that
form myloids in human disease; they can also be generated from sequences that do not form amyloids
naturally [30–32]. The implication is that amyloid assembly reactions have the inherent potential
to pr duce toxic species irrespective of the amyloidogenic precurs r. Analyses of the mec anisms
of toxicity have revealed that cellular m mb anes are a major target f r prefib illar oligomers, with
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membrane permeabilisation resulting in elevated intracellular Ca2+, the induction of oxidative stress
and cell death [31,33,34].
Whilst prefibrillar oligomers are important participants in amyloid disease, they can be transient
and heterogenous in nature [28,29]. For example, there are multiple different oligomeric forms of
Aβ: dimers, trimers, tetramers, pentamers, decamers, Aβ-derived diffusible ligands, dodecamers,
and Aβ*56 [35–40]. Moreover, oligomers can exhibit markedly different biological properties, with
the same peptide or protein producing both toxic and non-toxic oligomers [41,42]. Adding to this
complexity, prefibrillar oligomers are unlikely to be the only toxic species associated with amyloids.
Fibrils exhibit a range of disease-relevant properties, including the capacity to damage membranes
either via direction interaction or by elongating on the membrane surface [43–46]. Fibrils can also act
as an additional source of oligomers by either shedding from their ends or by providing a surface
that catalyses new oligomer formation [45,47–49]. Thus, when examining the mechanisms of amyloid
toxicity, an array of prefibrillar oligomers, fibrils, and fibril-derived oligomers need to be considered.
4. Functional Amyloids and Their Physiological Roles in Humans
Amyloids can also be produced as a natural protein fold with the fibrils performing an array
of physiological functions. The fibrous structure of amyloid fibrils facilitates their use as scaffolds
for biochemical processes, whereas the compact nature of the amyloid fold is ideal for the storage
of proteins and peptides. In humans, several different peptides and proteins have been shown to
self-assemble into fibrils that perform physiological functions and that have properties consistent with
amyloids [11–21]. The experimental evidence for the formation of amyloid fibrils by these peptides and
proteins is summarised in Table 1. For clarity, in this article, the term amyloid is used when a cross-β
X-ray fiber diffraction pattern and amyloid-specific dye binding have both been demonstrated. Fibrils
that bind amyloid-specific dyes, but that have not been shown experimentally to have a cross-β
structure, will be referred to as amyloid-like.
Amyloid fibrils of pigment cell-specific pre-melanosomal protein (PMEL) are localised to the
lumen of melanosomes, a specialised organelle present in the skin and eyes that acts as the site for the
synthesis of the pigment melanin [17,50,51]. The fibrils are thought to be scaffolds for the deposition of
the tyrosine-based polymer melanin, sequestering toxic intermediates in melanin synthesis [17,50,51].
An analogous scaffold function has been proposed for receptor-interacting protein 1 (RIP1)/RIP3
amyloid fibrils [20]. In regulated necrosis, RIP1 and RIP3 kinases co-assemble into heterodimeric
amyloid fibrils that act as a signalling complex known as the necrosome [52]. The necrosome recruits
free RIP3, resulting in its autophosphorylation and the subsequent recruitment and phosphorylation
of mixed-lineage kinase domain-like (MLKL), a key downstream substrate in regulated necrosis [52].
In cells subjected to stressors amyloid-bodies (A-bodies) act as stores for proteins [11]. Both
acidosis and heat shock induce the expression of ribosomal intergenic noncoding RNA (rIGSRNA),
which seeds A-body formation in the nucleus [11]. Multiple proteins (>180) assemble into the A-bodies,
including proteins involved in cell cycle progression and DNA synthesis, resulting in cells entering
a dormant state [11]. Conversely, the removal of the stressor causes A-bodies to disassemble [11].
Similarly, many peptide hormones are stored as amyloid fibrils in the acidic lumen of the secretory
granules in endocrine cells [16]. The high density of the amyloid fibrils is thought to give the granules
their characteristic dense core. However, upon granule secretion, the fibrils will dissociate into the
monomeric form of the peptide hormone due to exposure to the higher extracellular pH [16].
Antimicrobial peptides (AMPs) play a central role in innate immune responses to infection [53].
They share a number of characteristics with the peptides and proteins that form amyloids, with both
AMPs and amyloidogenic sequences being able to form pores that permeabilise membranes [53,54].
Moreover, the AMPs LL-37 and protegrin-1 can assemble into amyloid-like fibrils, suggesting that they,
and potentially other human AMPs, can also be classified as functional amyloids [15,19].
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Table 1. Functional amyloids: summary of the experimental evidence for the formation of
amyloid fibrils.
Protein, Peptide or
Cellular Structure Proposed Functions Experimental Evidence for Amyloid Fibrils
Amyloid-bodies (A-bodies) Stores of proteins instressed cells
A-bodies are stained by Congo red and thioflavin-S.
Proteins that accumulate in A-bodies can form fibrils with





Acrosomes in sperm are stained by thioflavin-S and are
recognised by amyloid-specific antibodies. Purified









Material from the epididymis has a cross cross-β X-ray
fiber diffraction pattern, is recognised by amyloid-specific
antibodies and binds thioflavin-S and Congo red. CRES
proteins co-localises with thioflavin-S. Fibrils of CRES
proteins bind thioflavin-T and are recognised by
amyloid-specific antibodies [13,14].
LL-37 Antimicrobial Fibrils exhibit green birefringence with Congo red [15].
Peptide hormones Storage of the hormone insecretory granules
Purified granules from endocrine cells have a cross-β
X-ray fiber diffraction pattern and exhibit green
birefringence with Congo red. The fibrils bind Congo red





Purified melansomes are stained by thioflavin-S and
Congo red. The fibrils have a cross-β X-ray fiber
diffraction pattern, bind Congo red and thioflavin-T and
have a far ultraviolet circular dichroism spectrum
consistent with β-sheet content [17].
Prostatic acid phosphatase
peptides Removal of damaged sperm
The fibrils have a cross-β X-ray fiber diffraction pattern,
bind thioflavin-T and exhibit green birefringence with
Congo red [18].
Protegrin-1 Antimicrobial The fibrils bind thioflavin-T [19].
Receptor-interacting
protein 1 (RIP1)/RIP3 Regulated necrosis
The fibrils have a cross-β X-ray fiber diffraction pattern,
a solid state NMR spectra consistent with a β-sheet core
and bind thioflavin T and Congo red [20].
Semenogelin proteins
(SEM1 and SEM2) Removal of damaged sperm
The fibrils bind thioflavin-T and Congo red and an
amyloid-specific antibody pulls down SEM 1 and SEM 2
from seminal fluid [21].
Functional amyloid fibrils have also been proposed to participate in sexual reproduction [55].
Amyloid fibrils are present in the sperm acrosome, an acidic organelle in the sperm head [12]. These
fibrils are thought to facilitate the controlled release of proteins during the acrosome reaction, a key
event in the fertilisation of oocytes in which the contents of the acrosome are released [12,55,56].
Amyloids formed by the cystatin-related epididymal spermatogenicis (CRES) subgroup proteins CRES,
CRES2, CRES3, and cystatin E2 are present in the epididymis [13,14]. Although the role of amyloids
formed by the CRES proteins is not well understood, CRES has antimicrobial activity, is important
for the acrosome reaction, and is required for normal lysosomal function in the epididymis [13,57–59].
Seminal fluid also contains amyloids and amyloid-like fibrils, formed respectively by peptide fragments
of enzyme prostatic acid phosphatase (PAP) and semenogelin proteins (SEM1 and SEM2) [18,21].
Originally identified as enhancers of viral infection [18,21], these fibrils bind to and immobilise
damaged sperm cells enabling their clearance by immune cells [60].
Artificial nanomaterials that use amyloid fibrils as a scaffold for the growth of cells can be
used as functional amyloids. For example the peptide TTR1-RGD combines residues 105–115 of the
human amyloidogenic protein transthyretin and the three amino acid cell adhesion motif RGD from
fibronectin [61]. This peptide forms amyloid fibrils that can support the adhesion and growth of
fibroblasts [61]. In another study, hen-egg white lysozyme amyloid fibrils were used as a substitute
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for collagen in a bone biomimetic composite, which was able to support the adhesion and growth of
pre-osteoblast cells [62].
5. Does Functional Amyloid Fibril Assembly Generate Toxic Species?
Given the potential for the production of toxic species in amyloid assembly reactions, it is
remarkable that under normal circumstances cells can produce functional amyloids fibrils without
any obvious deleterious consequences. Is this because functional amyloids are intrinsically non-toxic
to human cells? A number of studies indicate that this is not the case; thus, the distinction between
functional amyloids and pathological amyloids is not always clear-cut.
Amyloid fibrils formed from the peptide hormones glucagon, α-helical corticotropin-releasing
factor, glucagon-like peptide 2, and urocortin 3 reduce cell viability when incubated with cultured cells
and primary neurons [16]. Likewise, amyloid fibrils formed by the seminal PAP peptide fragment are
toxic to a neuronal cell line [63]. Perturbation of PMEL fibril assembly may also result in the production
of toxic amyloids. PMEL is synthesised as a transmembrane glycoprotein precursor; subsequent
proteolytic processing releases the N-terminal Mα fragment that forms the fibril core [17,50,51,64–68].
The chicken PMEL Dominant White (DW) mutation results in the formation of abnormal compact
fibrillar structures in cells, the loss of melanosomes and reduced cell viability [50,51,69,70]. Crucially,
this is a more severe phenotype that of the mouse PMEL knockout, which only results in a modest
loss of pigmentation [71]. The DW mutant has a three-amino acid insertion in the transmembrane
domain, a region of the protein that does not form part of the Mα fibril core [70]. This mutation
has no effect on either the trafficking of PMEL to melanosomes or on its proteolytic processing, but
instead causes abnormal oligomerisation of the transmembrane domain and/or association with
membranes [69]. This may alter the assembly of PMEL resulting in the formation of increased numbers
of toxic oligomers or the formation of abnormal fibril polymorphs that are toxic to the cells [69].
Surprisingly, the archetype disease-associated amyloid Aβ may itself be a functional amyloid that
acts as an AMP [72–74]. Aβ exhibits antimicrobial properties that target pathogenic bacteria and fungi
in vitro and in Caenorhabditis elegans and mouse models [72,73]. The aggregation of Aβ into amyloids
is central to its proposed antimicrobial properties, with assembly intermediates and amyloid fibrils
interacting with microbial cell walls to inhibit microbial adhesion to host cells and to agglutinate the
microorganisms [72–74]. Consistent with an antimicrobial role for Aβ, there are clear parallels with
AMPs such as LL-37. Indeed, LL-37 not only exhibits antimicrobial properties and forms amyloid-like
fibrils, but can also be toxic to host cells [73,75–79].
The potential for the toxicity of amyloids is also relevant for the biocompatibility of nanomaterials
that incorporate amyloid fibrils. Whilst TTR1-RGD amyloid fibrils can support cell growth initially,
a reduction in cell viability is observed in longer-term cultures using these fibrils as a scaffold for
cells [61,80]. Though in this instance toxicity could be associated with the use of the TTR1 sequence
from transythretin, a protein which forms amyloids in transythretin amyloidosis [4–7].
It is also worth noting that the induction of cell death can be a normal physiological function of
amyloids, with RIP1- and RIP3-forming amyloid fibrils in cells undergoing regulated necrosis [20].
Cell death is thought to be induced via the activation of RIP3 kinase substrates and not via the
formation of toxic amyloid species [20], although any coincidental toxicity associated with RIP1/RIP3
fibril formation could amplify the necrotic effects of the signaling pathway. RIP1/RIP3 mediated
necrosis is also activated in pathological processes such as ischemic injury and damaging inflammatory
processes [81]. Thus, even though their normal function is performed, RIP1/RIP3 fibrils can be
involved in disease.
6. How Do Cells Avert Toxicity in Functional Amyloid Assembly?
The potential for toxicity exhibited by amyloid fibrils and their assembly intermediates highlights
that functional amyloid assembly must be tightly controlled. A full picture for how cells prevent
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Figure 2. How human cells prevent functional amyloids from causing toxicity? (1) Controlling the level
of the amyloidogenic peptides and proteins by regulating its expression, degradation, and generation by
proteolysis of a protein precursor will prevent the overproduction of amyloids. (2) The rapid assembly
of fibrils will reduce the production of any potentially toxic prefibrillar oligomers. (3) Molecules,
such as glycosaminoglycans (GAGs) and ribosomal intergenic noncoding RNA (rIGSRNA), promote
amyloid assembly ensuring it only occurs when and where required. These molecules may also
promote rapid fibril assembly and prevent unwanted interactions with other cellular components.
(4) Sequestering assembly and storage of amyloids within membrane bound organelles will prevent
unwanted interactions with other cellular components. (5) The ability to disassemble functional
amyloids, under physiological conditions, with chaperones or by exposure to higher pH, will ensure
that the fibrils can be removed when no longer required.
6.1. Regulating the Level of the Amyloidogenic Peptides and Proteins
Elevated levels of amyloidogenic peptides and proteins either through increased expression,
decreased degradation or a combination thereof, are thought to be a key factor in the development
of amyloidoses [82,83]. For example, Alzheimer’s disease and DRA are associated with elevated
levels of monomeric Aβ peptides and β2m respectively, which can result in their aggregation [84,85].
Thus, the level of the precursors of functional fibrils amyloids will require tight regulation, as too
much of the amyloidogenic precursor could lead to unwanted amyloid formation. Indeed, given the
antimicrobial activity of Aβ [72–74] and the role attributed to inflammation in Alzheimer’s disease [86],
it is tempting to speculate that amyloid formation and cellular toxicity in Alzheimer’s disease could
also result from overproduction of Aβ peptides in dysregulated immune responses to either infection
or sterile inflammation.
Proteolytic processing may represent one mechanism cells use to regulate the level of
amyloidogenic peptides and proteins. Analogous to Aβ peptides, which are generated by cleavage
of the amyloid precursor protein by β-secretases and γ-secretases, PMEL is processed by proteases
prior to assembling into amyloids [51,64–68,87]. The endoplasmic reticulum is the site of synthesis of
PMEL and the protein traffics to by melanosomes via the Golgi apparatus and early endosomes [51].
PMEL is subjected to proteolytic cleavage in the trans-Golgi network and endosomes to liberate the
fibril forming Mα fragment [64–68]. Thus, proteolytic processing may not only regulate the level of
the Mα fragment, but it will also ensure that PMEL amyloid fibrils do not assemble prematurely in the
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secretory pathway. Proteolytic processing may also regulate the production of seminal amyloid and
amyloid-like fibrils, which are formed by peptide fragments of PAP and semenogelin proteins [18,21].
6.2. Minimising the Production of Prefibrillar Oligomers
Little is known about the oligomers produced in the assembly of functional amyloids. Nonetheless,
these assembly reactions must pose a particular risk for cells due to the inherent potential for the
production of toxic oligomers when amyloids are assembled [30–32]. Indeed, both acrosomes and
the epididymis contain material recognised by the antibody A11, which binds to toxic prefibrillar
oligomers generated from an array of different amyloidogenic precursors [12,13,25]. Thus, it may not
be possible to prevent the formation of toxic prefibrillar oligomers in functional amyloid assembly.
Functional amyloid assembly may instead minimise the formation of toxic prefibrillar oligomers to
below a threshold that causes deleterious effects. PMEL may achieve this by assembling into fibrils at
a rate that is orders of magnitude faster than that observed for the disease-associated sequences Aβ1-40
and α-synuclein [17]. This rapid assembly of fibrils should minimise the level of prefibrillar PMEL
oligomers, limiting their ability to cause toxicity. It is unknown, however, whether rapid assembly
is a feature of other functional amyloid fibrils. Furthermore, it is important to note that prefibrillar
oligomers are only one potential source of toxicity, with mature amyloid fibrils and fibril-derived
oligomers also exhibiting deleterious effects [43–45,47–49].
6.3. Controlling Assembly of Functional Amyloid Fibrils with other Molecules
An additional level of regulation to the assembly of a number of functional amyloid fibrils may
be provided by molecules that promote fibril assembly, ensuring fibrils only form when and where
required. Proteins stored in A-bodies have an amyloid-converting motif (ACM), which corresponds to
an arginine/histidine rich region flanking an amyloidogenic stretch of residues [11]. Yet these proteins
do not form amyloids spontaneously in cells. Instead expression of rIGSRNA induced by stressors
is required to seed assembly of proteins with ACMs into fibrils, potentially via interaction between
the RNA and the arginine/histidine rich region flanking the amyloidogenic stretch [11]. Similarly,
many of the peptide hormones stored within endocrine granules as amyloid fibrils do not form fibrils
spontaneously in vitro at the acidic pH of the granule lumen [16]. Amyloid formation by many of
these peptides is stimulated by glycosaminoglycans (GAGs), which are also present within endocrine
granules [16,88]. In addition to their role in promoting functional amyloid assembly these molecules
may help to prevent toxicity. Indeed, it has been shown that GAGs by accelerating fibril formation
can reduce toxicity associated with amyloid assembly reactions, presumably by lowering the level
and lifespan of prefibrillar oligomers [89–91]. Moreover, GAGs can prevent the disruption of lipid
membranes by preformed amyloid fibrils [92].
6.4. Sequestering Functional Amyloid Assembly Reactions within Membrane Bound Compartments
PMEL assembles into fibrils within early endosomes and melanosomes, whereas amyloid fibrils
formed by peptide hormones and acrosomal matrix proteins assemble within the lumen of endocrine
granules and acrosomes, respectively [12,16,17]. These membrane bound organelles provide an
acidic environment that is optimal for the assembly of the amyloid fibrils [12,16,17,50,51]. The
surrounding membrane may also act as a physical barrier to prevent unwanted interactions between
amyloids and other cellular components. Yet, the sequestration of amyloids within membrane bound
organelles may itself present a problem. Membranes are a key cellular target in amyloidoses, with
prefibrillar oligomers, amyloid fibrils, and fibril-derived oligomers being shown to permeabilise lipid
membranes [33,34,43–45]. The extent of membrane disruption is, however, dependent on the lipid
composition of the membranes [93,94]. This may be reflected in the lipid profiles of organelles in which
functional amyloids are assembled.
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6.5. Disassembly of Functional Amyloid Fibrils
Amyloidoses are characterised by the progressive accumulation of amyloid deposits, suggesting
that these diseases are caused, at least in part, by a failure to remove these unwanted protein
aggregates [82,83]. In contrast, a number of functional amyloids have been shown to disassemble
readily under physiological conditions. A-body formation in the nucleus is reversible, the removal of
the stressors resulting in their chaperone-dependent disassembly [11]. PMEL amyloid fibrils, as well
as those formed by peptide hormones and acrosomal proteins are localised to acidic organelles and
disassemble when exposed to neutral pH [12,16,95,96]. Moreover, no stable oligomers are observed
when fibrils of the PMEL repeat domain, which is part of the Mα fragment, disassemble at neutral
pH [96]. The ability to disassemble rapidly into monomers is clearly important for the function of
peptide hormones and may facilitate the dispersal of acrosomal matrix proteins during the acrosome
reaction. It will also ensure that fibrils released by cells disassemble into monomers before either the
fibrils or fibril-derived oligomers have the opportunity to cause any deleterious effects. Similarly, if
the membranes surrounding the organelles in which amyloid fibrils are localised become damaged,
any fibrils that inadvertently access the cytosol would presumably also rapidly disassemble.
7. Summary and Remaining Questions
In summary, functional amyloid fibrils participate in an array of physiological processes, but their
assembly could pose significant risks for cells. A number of mechanisms that may help avert the toxicity
of functional amyloids and their assembly intermediates can be proposed. These include regulating
the levels of amyloidogenic peptides and proteins, minimising the formation of prefibrillar oligomers,
sequestering fibril assembly inside membrane bound compartments, regulating assembly with GAGs
and RNAs and being able to disassemble amyloid fibrils. However, questions still remain about why
functional amyloids have no pronounced ill effect on the cells responsible for their production.
• Does the dysregulation of functional amyloid production result in disease? Of particular interest
is whether Alzheimer’s disease is caused by the overproduction of a functional amyloid.
• Do functional amyloid assembly reactions produce toxic oligomers? Studies suggest that toxic
prefibrillar oligomers are a common feature of amyloid assembly, yet surprisingly little is known
about the properties of oligomers associated with functional amyloids.
• Are functional amyloids able to assemble more rapidly than disease-associated amyloids, thus
limiting the production of any toxic prefibrillar oligomers?
• In addition to promoting the assembly of functional amyloids do rIGSRNA and GAGs also
prevent amyloid toxicity?
• How can functional amyloid fibrils be assembled and stored within membrane bound
compartments when cellular membranes represent a key target in amyloid toxicity?
Crucially, a better understanding of how cells prevent toxicity in the production of functional
amyloids will provide insights into how to prevent tissue degeneration in amyloidoses.
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